16,578,947 Shares FirstMerit Corporation Common Stock UNDERWRITING AGREEMENT
Exhibit 1.1
16,578,947 Shares
FirstMerit Corporation
Common Stock
May 17, 2010
RBC Capital Markets Corporation
Xxx Xxxxxxx Xxxxx
Xxx Xxxx, XX 00000
Xxx Xxxxxxx Xxxxx
Xxx Xxxx, XX 00000
Sandler X’Xxxxx & Partners, L.P.
000 Xxxxx Xxxxxx
Xxx Xxxx, XX 00000
000 Xxxxx Xxxxxx
Xxx Xxxx, XX 00000
As Representatives of the Several Underwriters
Dear Sirs:
1. Introductory. FirstMerit Corporation, a bank holding company registered under the Bank
Holding Company Act of 1956, as amended (the “BHCA”), and an Ohio corporation (“Company”), agrees
with the several Underwriters named in Schedule A hereto (“Underwriters”) to issue and sell
to the several Underwriters 16,578,947 shares (“Firm Securities”) of its common stock, no par value
(“Common Stock”), and also proposes to issue and sell to the Underwriters, at the option of the
Underwriters, an aggregate of not more than 2,486,842 additional shares (“Optional Securities”) of
its Common Stock as set forth below. The Firm Securities and the Optional Securities are herein
collectively called the “Shares”.
On May 14, 2010, prior to the offering of the Shares contemplated hereby and the execution of
this Agreement, the Company, through its subsidiary FirstMerit Bank, National Association
(“FirstMerit Bank”), assumed substantially all of the deposits and certain identified liabilities
and acquired certain assets of Midwest Bank and Trust Company, an Illinois state-chartered bank
and a wholly-owned subsidiary of Midwest Banc Holdings, Inc., from the Federal Deposit Insurance
Corporation (“FDIC”), as receiver, in accordance with the terms of a purchase and assumption
agreement dated May 14, 2010 (the “Purchase and Assumption Agreement”) as described in the
Preliminary Prospectus Supplement (as defined below) under the heading “Prospectus Supplement
Summary—Recent Developments” (collectively, the “Acquisition”). The Purchase and Assumption
Agreement, the FirstMerit Bank Cash-Settled Value Appreciation Instrument dated May 14, 2010 and
the Escrow Agreement dated May 14, 2010 are herein collectively called the “Acquisition Agreement.”
2. Representations and Warranties of the Company. The Company represents and warrants to, and
agrees with, the several Underwriters that:
(a) Filing and Effectiveness of Registration Statement; Certain Defined Terms. The
Company has filed with the Commission a registration statement on Form S-3ASR (No.
333-157163), including a related prospectus or prospectuses, covering the registration of
the Shares under the Act, which has become effective. “Registration Statement” at any
particular time means such registration statement in the form then filed with the
Commission, including any amendment thereto, any document incorporated by reference therein
and all 430B Information and all 430C Information with respect to such registration
statement, that in any case has not been superseded or modified. “Registration Statement”
without reference to a time means the Registration Statement as of the Effective Time. For
purposes of this definition, 430B Information shall be considered to be included in the
Registration Statement as of the time specified in Rule 430B.
For purposes of this Agreement:
“430B Information” means information included in a prospectus then deemed to be a part
of the Registration Statement pursuant to Rule 430B(e) or retroactively deemed to be a part
of the Registration Statement pursuant to Rule 430B(f).
“430C Information” means information included in a prospectus then deemed to be a part
of the Registration Statement pursuant to Rule 430C.
“Act” means the Securities Act of 1933, as amended.
“Applicable Time” means 7:30 p.m. (Eastern time) on the date of this Agreement.
“Closing Date” has the meaning defined in Section 3 hereof.
“Commission” means the Securities and Exchange Commission.
“Effective Time” of the Registration Statement relating to the Shares means the time of
the first contract of sale for the Shares.
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
“Final Prospectus” means the Statutory Prospectus that discloses the public offering
price, other 430B Information and other final terms of the Shares and otherwise satisfies
Section 10(a) of the Act.
“General Use Issuer Free Writing Prospectus” means any Issuer Free Writing Prospectus
that is intended for general distribution to prospective investors, as evidenced by its
being so specified in Schedule B to this Agreement.
2
“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined
in Rule 433, relating to the Shares in the form filed or required to be filed with the
Commission or, if not required to be filed, in the form retained in the Company’s records
pursuant to Rule 433(g).
“Limited Use Issuer Free Writing Prospectus” means any Issuer Free Writing Prospectus
that is not a General Use Issuer Free Writing Prospectus.
“Representatives” means Credit Suisse Securities (USA) LLC, RBC Capital Markets
Corporation and Sandler X’Xxxxx & Partners, L.P.
“Rules and Regulations” means the rules and regulations of the Commission.
“Securities Laws” means, collectively, the Xxxxxxxx-Xxxxx Act of 2002
(“Xxxxxxxx-Xxxxx”), the Act, the Exchange Act, the Rules and Regulations, the auditing
principles, rules, standards and practices applicable to auditors of “issuers” (as defined
in Xxxxxxxx-Xxxxx) promulgated or approved by the Public Company Accounting Oversight Board
and the rules of the NASDAQ Global Select Market (“NASDAQ Rules”).
“Significant Subsidiary” means a significant subsidiary as defined in Rule 405.
“Statutory Prospectus” with reference to any particular time means the prospectus
relating to the Shares that is included in the Registration Statement immediately prior to
that time, including all 430B Information and all 430C Information with respect to the
Registration Statement and including the documents incorporated by reference therein
pursuant to Item 12 of Form S-3 under the Securities Act, as of the date of such prospectus.
For purposes of the foregoing definition, 430B Information shall be considered to be
included in the Statutory Prospectus only as of the actual time that a form of prospectus
(including a prospectus supplement) is filed with the Commission pursuant to Rule 424(b) and
not retroactively.
Unless otherwise specified, a reference to a “Rule” is to the indicated rule under the Act.
(b) Compliance with Securities Act Requirements. (i) (A) At the time the Registration
Statement initially became effective, (B) at the time of each amendment thereto for the
purposes of complying with Section 10(a)(3) of the Act (whether by post-effective amendment,
incorporated report or form of prospectus), (C) at the Effective Time relating to the Shares
and (D) on the Closing Date, the Registration Statement conformed and will conform in all
material respects to the requirements of the Act and the Rules and Regulations and did not
and will not include any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein not
misleading and (ii) (A) on its date, (B) at the time of filing the Final Prospectus pursuant
to Rule 424(b) and (C) on the Closing Date, the Final Prospectus will conform in all
material respects to the requirements of the Act and the Rules and Regulations, and will not
include any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading. The preceding sentence does not
apply to statements in, or omissions from, any such document based upon written information
furnished to the Company by any Underwriter through the Representatives specifically for use
therein, it being understood and agreed that the only such information is that described as
such in Section 8(b) hereof. The documents incorporated by reference in the Statutory
Prospectus, when they became effective or were filed with the
3
Commission, as the case may be, conformed in all material respects with the
requirements of the Act or the Exchange Act, as applicable, and the Rules and Regulations
and did not include any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statement therein not
misleading.
(c) Automatic Shelf Registration Statement.
(i) Well-Known Seasoned Issuer Status. (A) At the time of initial filing of the
Registration Statement, (B) at the time of the most recent amendment thereto for the
purposes of complying with Section 10(a)(3) of the Act (whether such amendment was
by post-effective amendment, incorporated report filed pursuant to Section 13 or
15(d) of the Exchange Act or form of prospectus), and (C) at the time the Company or
any person acting on its behalf (within the meaning, for this clause only, of Rule
163(c)) made any offer relating to the Shares in reliance on the exemption of Rule
163, the Company was a “well known seasoned issuer” as defined in Rule 405,
including not having been an “ineligible issuer” as defined in Rule 405.
(ii) Effectiveness of Automatic Shelf Registration Statement. The Registration
Statement is an “automatic shelf registration statement,” as defined in Rule 405,
that initially became effective on February 6, 2009.
(iii) Eligibility to Use Automatic Shelf Registration Form. The Company has
not received from the Commission any notice pursuant to Rule 401(g)(2) objecting to
use of the automatic shelf registration statement form. If at any time the Company
receives from the Commission a notice pursuant to Rule 401(g)(2) or otherwise ceases
to be eligible to use the automatic shelf registration statement form, the Company
will (i) promptly notify the Representatives, (ii) promptly file a new registration
statement or post-effective amendment on the proper form relating to the Shares, in
a form reasonably satisfactory to the Representatives, (iii) use its best efforts to
cause such registration statement or post-effective amendment to be declared
effective as soon as practicable, and (iv) promptly notify the Representatives of
such effectiveness. The Company will take all other action necessary or appropriate
to permit the public offering and sale of the Shares to continue as contemplated in
the registration statement that was the subject of the Rule 401(g)(2) notice or for
which the Company has otherwise become ineligible. References herein to the
Registration Statement shall include such new registration statement or
post-effective amendment, as the case may be.
(iv) Filing Fees. The Company has paid or shall pay the required Commission
filing fees relating to the Shares within the time required by Rule 456(b)(1)
without regard to the proviso therein and otherwise in accordance with Rules 456(b)
and 457(r).
(d) Ineligible Issuer Status. (i) At the earliest time after the filing of the
Registration Statement that the Company or another offering participant makes a bona fide
offer (within the meaning of Rule 164(h)(2)) of the Shares and (ii) at the date of this
Agreement, the Company was not and is not an “ineligible issuer,” as defined in Rule 405,
including (x) the Company or any other subsidiary in the preceding three years not having
been convicted of a felony or misdemeanor or having been made the subject of a judicial or
administrative decree or order as described in Rule 405 and (y) the Company in the preceding
three years not having been the subject of a bankruptcy petition or insolvency or similar
proceeding, not having had a registration statement be the subject of a proceeding under
Section 8 of the Act and not being the subject of a proceeding under Section 8A of the Act
in connection with the offering of the Shares, all as described in Rule 405.
4
(e) General Disclosure Package. As of the Applicable Time, neither (i) the General Use
Issuer Free Writing Prospectus(es) issued at or prior to the Applicable Time and the
preliminary prospectus supplement, dated May 17, 2010 (the “Preliminary Prospectus
Supplement”), including the base prospectus, dated February 6, 2009 (which is the most
recent Statutory Prospectus distributed to investors generally), and the other information,
if any, stated in Schedule B to this Agreement to be included in the General
Disclosure Package, all considered together (collectively, the “General Disclosure
Package”), nor (ii) any individual Limited Use Issuer Free Writing Prospectus, when
considered together with the General Disclosure Package, included any untrue statement of a
material fact or omitted to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not
misleading. The preceding sentence does not apply to statements in, or omissions from, any
Statutory Prospectus, any Issuer Free Writing Prospectus or the General Disclosure Package
in reliance upon, and in conformity with, written information furnished to the Company by
any Underwriter through the Representatives specifically for use therein, it being
understood and agreed that the only such information furnished by any Underwriter consists
of the information described as such in Section 8(b) hereof.
(f) Issuer Free Writing Prospectuses. Each Issuer Free Writing Prospectus, as of its
issue date and at all subsequent times through the completion of the public offer and sale
of the Shares or until any earlier date that the Company notified or notifies the
Representatives as described in the next sentence, did not, does not and will not include
any information that conflicted, conflicts or will conflict with the information then
contained in the Registration Statement. If at any time following issuance of an Issuer
Free Writing Prospectus there occurred or occurs an event or development as a result of
which such Issuer Free Writing Prospectus conflicted or would conflict with the information
then contained in the Registration Statement or as a result of which such Issuer Free
Writing Prospectus, if republished immediately following such event or development, would
include an untrue statement of a material fact or omitted or would omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading, (i) the Company has promptly notified or will
promptly notify the Representatives and (ii) the Company has promptly amended or will
promptly amend or supplement such Issuer Free Writing Prospectus to eliminate or correct
such conflict, untrue statement or omission.
(g) Good Standing of the Company. The Company has been duly incorporated and is an
existing corporation in good standing under the laws of the State of Ohio, with corporate
power and authority to own its properties and conduct its business as described in the
General Disclosure Package and the Final Prospectus; and the Company is duly qualified to do
business as a foreign corporation in good standing in all other jurisdictions in which its
ownership or lease of property or the conduct of its business requires such qualification,
except where the failure to so qualify would not be reasonably expected to result in a
Material Adverse Effect (as defined below).
(h) Subsidiaries. Each subsidiary of the Company has been duly incorporated and is
existing and in good standing under the laws of the jurisdiction of its incorporation, with
corporate power and authority to own its properties and conduct its business as described in
the General Disclosure Package and the Final Prospectus; and each subsidiary of the Company
is duly qualified to do business as a foreign corporation in good standing in all other
jurisdictions in which its ownership or lease of property or the conduct of its business
requires such qualification, except where the failure to so qualify would not be reasonably
expected to result in a Material Adverse Effect; all of the issued and outstanding capital
stock of each subsidiary of the Company has been duly authorized and validly issued and is
fully paid and is nonassessable (other than such assessment as may be
required pursuant to 12 U.S.C. § 55 with respect to the stock of
a national banking association); and
the capital stock of each subsidiary owned by the Company, directly or through subsidiaries,
is owned free from liens, encumbrances and defects. The Company’s sole Significant
Subsidiary is FirstMerit Bank.
5
(i)
Authorization and Description of the Shares. The Shares and all other outstanding
shares of capital stock of the Company have been duly authorized by the Company; the
authorized equity capitalization of the Company is as set forth in the General Disclosure
Package and the Final Prospectus; all outstanding shares of capital stock of the Company
are, and, when the Shares have been delivered and paid for in accordance with this Agreement
on each Closing Date, such Shares will have been, validly issued, fully paid and
nonassessable, and will conform to the information in the General Disclosure Package and the
Final Prospectus and to the description of the Common Stock contained in the Final
Prospectus; the shareholders of the Company have no preemptive rights with respect to the
Common Stock; and none of the outstanding shares of capital stock of the Company has been
issued in violation of any preemptive or similar rights of any security holder.
(j) No Finder’s Fee. Except as disclosed in the General Disclosure Package and the
Final Prospectus, there are no contracts, agreements or understandings between the Company
and any person that would give rise to a valid claim against the Company or any Underwriter
for a brokerage commission, finder’s fee or other like payment in connection with this
offering.
(k) Registration Rights. Except as disclosed in the General Disclosure Package and the
Final Prospectus, there are no contracts, agreements or understandings between the Company
and any person granting such person the right to require the Company to file a registration
statement under the Act with respect to any securities of the Company owned or to be owned
by such person or to require the Company to include such securities in the securities
registered pursuant to the Registration Statement or in any securities being registered
pursuant to any other registration statement filed by the Company under the Act
(collectively, “registration rights”), and any person to whom the Company has granted
registration rights has agreed not to exercise such rights within any of the lock-up periods
described in Section 5(k).
(l) Approval of Listing. On or before the Closing Date, the Shares will have been
approved for listing on the NASDAQ Global Select Market (“NASDAQ”), subject to notice of
issuance.
(m) Absence of Further Requirements. No consent, approval, authorization, or order of,
or filing or registration with, any person (including any governmental agency or body or any
court) is required in connection with the execution and delivery of this Agreement or the
consummation of the transactions contemplated by this Agreement (including, without
limitation, the offering, issuance and sale of the Shares by the Company and the entering
into and consummation of the Acquisition), except such as have been obtained, or made and
such as may be required under the notification requirements of NASDAQ (which shall be
delivered on or before the Closing Date) and state securities laws.
(n) Title to Property. Except as disclosed in the General Disclosure Package and the
Final Prospectus, the Company and its subsidiaries have good and marketable title to all
real properties and all other properties and assets owned by them, in each case free from
liens, charges, encumbrances and defects that would materially affect the value thereof or
materially interfere with the use made or to be made thereof by them; and, except as
disclosed in the General Disclosure Package and the Final Prospectus, the Company and its
subsidiaries hold any leased real or personal property under valid and enforceable leases
with no terms or provisions that would materially interfere with the use made or to be made
thereof by them.
(o) Absence of Defaults and Conflicts Resulting from Transaction. The execution,
delivery and performance of this Agreement, the issuance and sale of the Shares, the
execution, delivery and performance of the Acquisition Agreement and the consummation of the
Acquisition, will not result in a breach or violation of any of the terms and provisions of,
or constitute a default or a Debt Repayment
6
Triggering Event (as defined below) under, or result in the imposition of any lien,
charge or encumbrance upon any property or assets of the Company or any of its subsidiaries
pursuant to the charter or by-laws of the Company or any of its subsidiaries, any statute,
rule, regulation or order of any governmental agency or body or any court, domestic or
foreign, having jurisdiction over the Company or any of its subsidiaries or any of their
properties, or any material agreement or instrument to which the Company or any of its
subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to
which any of the properties of the Company or any of its subsidiaries is subject; a “Debt
Repayment Triggering Event” means any event or condition that gives, or with the giving of
notice or lapse of time would give, the holder of any note, debenture, or other evidence of
indebtedness (or any person acting on such holder’s behalf) the right to require the
repurchase, redemption or repayment of all or a portion of such indebtedness by the Company
or any of its subsidiaries.
(p) Absence of Existing Defaults and Conflicts. (i) Neither the Company nor any of its
subsidiaries is in violation of its respective charter or by-laws, limited liability
agreement or other organizational instruments or (ii) neither the Company nor any of its
subsidiaries is in violation of or in default (or with the giving of notice or lapse of time
would be in default) under any existing obligation, agreement, covenant or condition
contained in any indenture, loan agreement, mortgage, lease or other agreement or instrument
to which any of them is a party or by which any of them is bound or to which any of the
properties of any of them is subject, except, in the case of clause (ii) only, such
violations or defaults that would not, individually or in the aggregate, result in a
material adverse effect on the condition (financial or otherwise), results of operations,
business, properties or prospects of the Company and its subsidiaries taken as a whole
(“Material Adverse Effect”).
(q) Authorization of Agreements. Each of this Agreement and the Acquisition Agreement
has been duly authorized, executed and delivered by the Company. The Acquisition Agreement
constitutes a legal, valid and binding agreement of the Company, enforceable against the
Company in accordance with its terms, except as such enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting creditors’ rights generally and by general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or at law).
(r) Bank Holding Company; Possession of Licenses and Permits. The Company is duly
registered as a bank holding company under the BHCA. Except as would not individually or in
the aggregate have a Material Adverse Effect, the Company and its subsidiaries possess, and
are in compliance with the terms of, all certificates, authorizations, franchises, licenses
and permits (“Licenses”) and have made all filings, applications and registrations with all
courts, regulatory authorities or governmental agencies or bodies having jurisdiction over
the Company and its subsidiaries necessary to the conduct of the business now conducted or
proposed in the General Disclosure Package and the Final Prospectus to be conducted by them.
The Company and its subsidiaries have not received any notice of proceedings relating to the
revocation or modification of any Licenses that, if determined adversely to the Company or
any of its subsidiaries would individually or in the aggregate have a Material Adverse
Effect.
(s) No Enforcement. Except as disclosed in the General Disclosure Package and Final
Prospectus, neither the Company nor any subsidiary of the Company (i) is the subject of any
cease-and-desist order, operating agreement, written agreement, consent decree, memorandum
of understanding, commitment letter, order, directive, extraordinary supervisory letter or
similar action taken, issued or required by any governmental, regulatory, judicial,
self-regulatory or similar body or (ii) has been advised by any governmental, regulatory,
judicial, self-regulatory or similar body having jurisdiction over the Company and its
subsidiaries that it is considering taking, issuing or requiring any of the items in clause
(i). The Company and its subsidiaries are in compliance in all material respects with the
terms of any item listed in clause (i) that is disclosed in the General Disclosure Package
and Final Prospectus.
7
(t) Absence of Labor Dispute. No labor dispute with the employees of the Company or
any of its subsidiaries exists or, to the knowledge of the Company, is imminent that could
have a Material Adverse Effect.
(u) Possession of Intellectual Property. The Company and its subsidiaries own, possess
or can acquire on reasonable terms, adequate trademarks, trade names and other rights to
inventions, know-how, patents, copyrights, confidential information and other intellectual
property (collectively, “intellectual property rights”) necessary to conduct the business
now operated by them, or presently employed by them, and have not received any notice of
infringement of or conflict with asserted rights of others with respect to any intellectual
property rights that, if determined adversely to the Company or any of its subsidiaries,
would individually or in the aggregate have a Material Adverse Effect.
(v) Environmental Laws. Except as disclosed in the General Disclosure Package and the
Final Prospectus, neither the Company nor any of its subsidiaries is in violation of any
statute, rule, regulation, decision or order of any governmental agency or body or any
court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic
substances or relating to the protection or restoration of the environment or human exposure
to hazardous or toxic substances (collectively, “environmental laws”), owns or operates any
real property contaminated with any substance that is subject to any environmental laws, is
liable for any off-site disposal or contamination pursuant to any environmental laws, or is
subject to any claim relating to any environmental laws which violation, contamination,
liability or claim would individually or in the aggregate have a Material Adverse Effect;
and the Company is not aware of any pending investigation which might lead to such a claim.
(w) ERISA Compliance. Neither the Company nor any of its subsidiaries has any
liability for any prohibited transaction or accumulated funding deficiency (within the
meaning of Section 412 of the Internal Revenue Code) or any complete or partial withdrawal
liability (within the meaning of Sections 4203 and 4205 of the Employee Retirement Income
Security Act of 1974, as amended (“ERISA”), respectively), with respect to any pension,
profit sharing or other plan which is subject to ERISA, to which the Company or any of its
subsidiaries makes or ever has made a contribution and in which any employee of the Company
or any subsidiary is or has ever been a participant. With respect to such plans, the
Company and each of its subsidiaries is in compliance in all material respects with all
applicable provisions of ERISA.
(x) Company Website. All information on (or hyperlinked from) the Company’s website at
xxx.xxxxxxxxxx.xxx either (i) qualifies for the exemption for regularly released
factual business information or forward-looking information in Rule 168 of the Act or (ii)
qualifies for the safe-harbor related to historical information in Rule 433(e)(2) under the
Act.
(y) SEC Comments. The Company has not received any written comments from the
Commission staff in connection with the Company’s reports under the Exchange Act that remain
unresolved.
(z) Accurate Disclosure. The statements in the General Disclosure Package and the
Prospectus under the captions “Prospectus Supplement Summary—Recent Developments—Midwest
Bank Acquisition,” “U.S. Federal Tax Consequences to Non-U.S. Holders,” “Description of
Common Stock” and “Underwriting” and in the Company’s Annual Report on Form 10-K
incorporated by reference into the General Disclosure Package and the Prospectus under the
caption “Business—Regulation and Supervision”, insofar as such statements summarize legal
matters, agreements, documents or proceedings discussed therein, are accurate and fair
summaries of such legal matters, agreements, documents or proceedings and present the
information required to be shown.
8
(aa) Absence of Manipulation. The Company has not taken, directly or indirectly, any
action that is designed to or that has constituted or that would reasonably be expected to
cause or result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of the Shares.
(bb) Actively-Traded Security. The Common Stock is an “actively-traded security”
exempted from the requirements of Rule 101 of Regulation M under the Exchange Act by
subsection 101(c)(1) of such rule.
(cc) Statistical and Market-Related Data. Any third-party statistical and
market-related data included or incorporated by reference in a Registration Statement, a
Statutory Prospectus or the General Disclosure Package are based on or derived from sources
that the Company believes to be reliable and accurate.
(dd) Internal Controls and Compliance with the Xxxxxxxx-Xxxxx Act. Except as set forth
in the General Disclosure Package and the Final Prospectus, the Company, its subsidiaries
and the Company’s Board of Directors (the “Board”) are in compliance with Xxxxxxxx-Xxxxx and
all applicable Rules and Regulations. The Company maintains a system of internal controls,
including, but not limited to, internal controls over accounting matters and financial
reporting, an internal audit function and legal and regulatory compliance controls
(collectively, “Internal Controls”) that comply with the Securities Laws and are sufficient
to provide reasonable assurances that (i) transactions are executed in accordance with
management’s general or specific authorizations, (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with U.S. Generally Accepted
Accounting Principles and to maintain accountability for assets, (iii) access to assets is
permitted only in accordance with management’s general or specific authorization and (iv)
the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Internal
Controls over financial reporting are effective and the Company is not aware of any material
weakness in its Internal Control over financial reporting. Except as disclosed in the
General Disclosure Package and the Final Prospectus, since December 31, 2009, there has been
no change in the Internal Controls that has materially affected, or is reasonably likely to
materially affect, the Internal Controls. The Internal Controls are overseen by the Audit
Committee of the Board (the “Audit Committee”) in accordance with the Rules and Regulations.
The Company has not publicly disclosed or reported to the Audit Committee or the Board, and
within the next 90 days the Company does not reasonably expect to publicly disclose or
report to the Audit Committee or the Board, a significant deficiency, material weakness,
change in Internal Controls or fraud involving management or other employees who have a
significant role in Internal Controls (each, an “Internal Control Event”), any violation of,
or failure to comply with, the Securities Laws, or any matter which, if determined
adversely, would have a Material Adverse Effect. The Company maintains “disclosure controls
and procedures” (as such term is defined in Rule 13a-15(e) under the Exchange Act) that
comply with the requirements of the Exchange Act; such disclosure controls and procedures
have been designed to ensure that material information relating to the Company and its
subsidiaries is made known to the Company’s principal executive officer and principal
financial officer by others within those entities; and such disclosure controls and
procedures are effective.
(ee) Absence of Accounting Issues. A member of the Audit Committee has confirmed to
the Chief Executive Officer, Chief Financial Officer or General Counsel of the Company that,
except as set forth in the General Disclosure Package and the Final Prospectus, the Audit
Committee is not reviewing or investigating, and neither the Company’s independent auditors
nor its internal auditors have recommended that the Audit Committee review or investigate,
(i) adding to, deleting, changing the application of, or changing the Company’s disclosure
with respect to, any of the Company’s material accounting policies; (ii) any matter that
could result in a restatement of the Company’s financial statements for any annual or
interim period during the current or prior three fiscal years; or (iii) any Internal Control
Event.
9
(ff) Legal Proceedings. Except as disclosed in the General Disclosure Package and the
Final Prospectus, there are no pending actions, suits or proceedings (including any
inquiries or investigations by or before any court or governmental agency or body, domestic
or foreign) against or affecting the Company, any of its subsidiaries or any of their
respective properties that, if determined adversely to the Company or any of its
subsidiaries, would individually or in the aggregate have a Material Adverse Effect, or
would materially and adversely affect the ability of the Company to perform its obligations
under this Agreement, or which are otherwise material in the context of the sale of the
Shares; and no such actions, suits or proceedings (including any inquiries or investigations
by any court or governmental agency or body, domestic or foreign) are, to the Company’s
knowledge, threatened or contemplated.
(gg) Financial Statements. The financial statements included or incorporated by
reference in the Registration Statement and the General Disclosure Package present fairly
the financial position of the Company and its consolidated subsidiaries as of the dates
shown and their results of operations and cash flows for the periods shown, and such
financial statements have been prepared in conformity with the generally accepted accounting
principles in the United States applied on a consistent basis.
(hh) No Material Adverse Change in Business. Except as disclosed in the General
Disclosure Package and the Final Prospectus, since the end of the period covered by the
latest audited financial statements included or incorporated by reference in the General
Disclosure Package and the Final Prospectus (i) there has been no change, nor any
development or event involving a prospective change, in the condition (financial or
otherwise), results of operations, business, properties or prospects of the Company and its
subsidiaries, taken as a whole that is material and adverse, (ii) except as disclosed in or
contemplated by the General Disclosure Package and the Final Prospectus, there has been no
dividend or distribution of any kind declared, paid or made by the Company on any class of
its capital stock and (iii) except as disclosed in or contemplated by the General Disclosure
Package and the Final Prospectus, there has been no material adverse change in the capital
stock, short-term indebtedness, long-term indebtedness, net current assets or net assets of
the Company and its subsidiaries.
(ii) Investment Company Act. The Company is not and, after giving effect to the
offering and sale of the Shares and the application of the proceeds thereof as described in
the General Disclosure Package and the Final Prospectus, will not be an “investment company”
as defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”).
(jj) Ratings. No “nationally recognized statistical rating organization” as such term
is defined for purposes of Rule 436(g)(2) (i) has imposed (or has informed the Company that
it is considering imposing) any condition (financial or otherwise) on the Company’s
retaining any rating assigned to the Company or any securities of the Company or (ii) has
indicated to the Company that it is considering any of the actions described in Section
7(c)(ii) hereof.
(kk) Compliance with Certain Laws. Each of the Company, its subsidiaries, its
affiliates and any of their respective officers, directors, supervisors, managers, agents,
or employees, represents that it has not violated, its participation in the offering and
sale of the Shares contemplated by the this Agreement will not violate, and it has
instituted and maintains policies and procedures designed to ensure continued compliance
with each of the following laws: (a) anti-bribery laws, including but not limited to, any
applicable law, rule, or regulation of any locality, including but not limited to any law,
rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of
Foreign Public Officials in International Business Transactions, signed December 17, 1997,
including the U.S. Foreign Corrupt Practices Act of 1977 or any other law, rule or
regulation of similar purpose and scope, (b) anti-money laundering laws, including but not
limited to, applicable federal, state, international, foreign or other laws, regulations or
government guidance regarding anti-money laundering, including, without limitation, Title
10
18 U.S. Code section 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and
international anti-money laundering principles or procedures by an intergovernmental group
or organization, such as the Financial Action Task Force on Money Laundering, of which the
United States is a member and with which designation the United States representative to the
group or organization continues to concur, all as amended, and any Executive order,
directive, or regulation pursuant to the authority of any of the foregoing, or any orders or
licenses issued thereunder or (c) laws and regulations imposing U.S. economic sanctions
measures, including, but not limited to, the International Emergency Economic Powers Act,
the Trading with the Enemy Act, the United Nations Participation Act, and the Syria
Accountability and Lebanese Sovereignty Act, all as amended, and any Executive Order,
directive, or regulation pursuant to the authority of any of the foregoing, including the
regulations of the United States Treasury Department set forth under 31 CFR, Subtitle B,
Chapter V, as amended, or any orders or licenses issued thereunder.
(ll) Tax. The Company and its subsidiaries have filed all federal, state, local and
non-U.S. tax returns that are required to be filed or have requested extensions thereof
(except in any case in which the failure so to file would not have a Material Adverse
Effect). Except as set forth in the General Disclosure Package and the Final Prospectus,
the Company and its subsidiaries have paid all taxes (including any assessments, fines or
penalties) shown as due thereon, except for any such taxes, assessments, fines or penalties
that are not currently due and payable or that are being contested in good faith and for
which adequate reserves for the payment of such taxes have been maintained by the Company.
(mm) Use of Proceeds. Except as disclosed in the General Disclosure Package and the
Final Prospectus, the Company does not intend to use any of the proceeds from sale of the
Shares to repay any outstanding debt owed to any Underwriter or any affiliate of an
Underwriter.
(nn) Insurance. The Company and its subsidiaries are insured by insurers with
appropriately rated claims paying abilities against such losses and risks and in such
amounts as are customary for the businesses in which they are engaged; all policies of
insurance and fidelity or surety bonds insuring the Company or any of its subsidiaries or
their respective businesses, assets, employees, officers and directors are in full force and
effect; the Company and its subsidiaries are in compliance with the terms of such policies
and instruments in all material respects; and there are no material claims by the Company or
any of its subsidiaries under any such policy or instrument as to which any insurance
company is denying liability or defending under a reservation of rights clause; and neither
the Company nor any such subsidiary has any reason to believe that it will not be able to
renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business at a cost that
would not have a Material Adverse Effect, except as set forth in or contemplated in the
General Disclosure Package and the Final Prospectus.
(oo) The offer, issuance and sale of the Shares do not require any approval of the
Company’s shareholders, including without limitation pursuant to the rules and regulations
of NASDAQ.
3. Purchase, Sale and Delivery of the Shares. On the basis of the representations, warranties
and agreements and subject to the terms and conditions set forth herein, the Company agrees to sell
to the several Underwriters, and each of the Underwriters agrees, severally and not jointly, to
purchase from the Company, at a purchase price of $18.1925 per share, the respective number of
shares of Firm Securities set forth opposite the names of the Underwriters in Schedule A
hereto.
The Company will deliver the Firm Securities to or as instructed by the Representatives for
the accounts of the several Underwriters in a form reasonably acceptable to the Representatives
against payment of the purchase price by the Underwriters in Federal (same day) funds by wire
transfer to an account at a bank acceptable to the
11
Representatives drawn to the order of the Company at the office of Skadden, Arps, Slate,
Xxxxxxx & Xxxx LLP, Four Times Square, Xxx Xxxx XX 00000, at 10:00 a.m., New York time, on May 21,
2010, or at such other time not later than seven full business days thereafter as the
Representatives and the Company determine, such time being herein referred to as the “First Closing
Date”. For purposes of Rule 15c6-1 under the Exchange Act, the First Closing Date (if later than
the otherwise applicable settlement date) shall be the settlement date for payment of funds and
delivery of securities for all the Shares sold pursuant to the offering. The Firm Securities so to
be delivered or evidence of their issuance will be made available for checking at the above office
of Skadden, Arps, Slate, Xxxxxxx & Xxxx LLP at least 24 hours prior to the First Closing Date.
In addition, upon written notice from the Representatives given to the Company from time to
time not more than 30 days subsequent to the date of the Final Prospectus, the Underwriters may
purchase all or less than all of the Optional Securities at the purchase price per Security to be
paid for the Firm Securities. The Company agrees to sell to the Underwriters the number of shares
of Optional Securities specified in such notice and the Underwriters agree, severally and not
jointly, to purchase such Optional Securities. Such Optional Securities shall be purchased for the
account of each Underwriter in the same proportion as the number of shares of Firm Securities set
forth opposite such Underwriter’s name bears to the total number of shares of Firm Securities
(subject to adjustment by the Representatives to eliminate fractions) and may be purchased by the
Underwriters only for the purpose of covering over-allotments made in connection with the sale of
the Firm Securities. No Optional Securities shall be sold or delivered unless the Firm Securities
previously have been, or simultaneously are, sold and delivered. The right to purchase the Optional
Securities or any portion thereof may be exercised from time to time and to the extent not
previously exercised may be surrendered and terminated at any time upon notice by the
Representatives to the Company.
Each time for the delivery of and payment for the Optional Securities, being herein referred
to as an “Optional Closing Date”, which may be the First Closing Date (the First Closing Date and
each Optional Closing Date, if any, being sometimes referred to as a “Closing Date”), shall be
determined by the Representatives but shall be no later than five full business days after written
notice of election to purchase Optional Securities is given. The Company will deliver the Optional
Securities being purchased on each Optional Closing Date to or as instructed by the Representatives
for the accounts of the several Underwriters in a form reasonably acceptable to the Representatives
against payment of the purchase price therefor in Federal (same day) funds by wire transfer to an
account at a bank acceptable to the Representatives drawn to the order of the Company, at the above
office of Skadden, Arps, Slate, Xxxxxxx & Xxxx LLP. The Optional Securities being
purchased on each Optional Closing Date or evidence of their issuance will be made available for
checking at the above office of Skadden, Arps, Slate, Xxxxxxx & Xxxx LLP at a reasonable time in
advance of such Optional Closing Date.
4. Offering by Underwriters. It is understood that the several Underwriters propose to offer
the Shares for sale to the public as set forth in the Final Prospectus.
5. Certain Agreements of the Company. The Company agrees with the several Underwriters that:
(a) Filing of Prospectuses. The Company has filed or will file each Statutory
Prospectus (including the Final Prospectus) pursuant to and in accordance with Rule
424(b)(2) (or, if applicable and consented to by the Representatives, subparagraph (5)) not
later than the second business day following the earlier of the date it is first used or the
execution and delivery of this Agreement. The Company has complied and will comply with
Rule 433 (including without limitation timely Commission filing where required).
(b) Filing of Amendments; Response to Commission Requests. The Company will promptly
advise the Representatives of any proposal to amend or supplement the Registration Statement
or any
12
Statutory Prospectus at any time and will offer the Representatives a reasonable
opportunity to comment on any such proposed amendment or supplement; and will file no such
amendment or supplement to which the Manager shall have reasonably objected in writing. The
Company will also advise the Representatives promptly of (i) the filing of any such proposed
amendment or supplement, (ii) any request by the Commission or its staff for any amendment
to the Registration Statement, for any supplement to any Statutory Prospectus or for any
additional information, (iii) the institution by the Commission of any stop order
proceedings in respect of the Registration Statement or the notice or threatening of any
proceeding for that purpose, and (iv) the receipt by the Company of any notification with
respect to the suspension of the qualification of the Shares in any jurisdiction or the
institution or threatening of any proceedings for such purpose. The Company will use its
best efforts to prevent the issuance of any such stop order or the suspension of any such
qualification and, if issued, to obtain as soon as possible the withdrawal thereof.
(c) Continued Compliance with Securities Laws. If, at any time when a prospectus
relating to the Shares is (or but for the exemption in Rule 172 would be) required to be
delivered under the Act by any Underwriter or dealer, any event occurs as a result of which
the Final Prospectus as then amended or supplemented would include an untrue statement of a
material fact or omit to state any material fact necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading, or if it is
necessary at any time to amend the Registration Statement or supplement the Final Prospectus
to comply with the Act, the Company will promptly notify the Representatives of such event
and will promptly prepare and file with the Commission and furnish, at its own expense, to
the Underwriters and the dealers and any other dealers upon request of the Representatives,
an amendment or supplement which will correct such statement or omission or an amendment
which will effect such compliance and will advise the Representatives when the Underwriters
are free to resume solicitation. Neither the Representatives’ consent to, nor the
Underwriters’ delivery of, any such amendment or supplement shall constitute a waiver of any
of the conditions set forth in Section 7 hereof.
(d) New Shelf. If immediately prior to the third anniversary (the “Renewal Deadline”)
of the initial effective date of the Registration Statement, any of the Shares remain unsold
by the Underwriters, the Company will prior to the Renewal Deadline file, if it has not
already done so and is eligible to do so, a new automatic shelf registration statement
relating to the Shares, in a form satisfactory to the Representatives. If the Company is no
longer eligible to file an automatic shelf registration statement, the Company will prior to
the Renewal Deadline, if it has not already done so, file a new shelf registration statement
relating to the Shares, in a form satisfactory to the Representatives, and will use its best
efforts to cause such registration statement to be declared effective within 180 days after
the Renewal Deadline. The Company will take all other action necessary or appropriate to
permit the public offering and sale of the Shares to continue as contemplated in the expired
registration statement relating to the Shares. References herein to the Registration
Statement shall include such new automatic shelf registration statement or such new shelf
registration statement, as the case may be. //
(e) Rule 158. As soon as practicable, but in any event no later than 16 months after
the date of this Agreement, the Company will make generally available to its securityholders
an earnings statement covering a period of at least 12 months beginning after the date of
this Agreement and satisfying the provisions of Section 11(a) of the Act and Rule 158.
(f) Furnishing of Prospectuses. The Company will furnish to the Representatives copies
of the Registration Statement, including all exhibits, any Statutory Prospectus, the Final
Prospectus and all amendments and supplements to such documents, in each case as soon as
available and in such quantities as the Representatives reasonably request. The Company
will pay the expenses of printing and distributing to the Underwriters all such documents.
13
(g) Blue Sky Qualifications. The Company will arrange for the qualification of the
Shares for offering and sale under the securities or blue sky laws of such states or other
jurisdictions as the Representatives designate and will maintain such qualifications in
effect so long as required for the distribution; provided, however, that the Company will
not be required to (i) qualify as a foreign corporation or other entity or as a dealer in
securities in any such jurisdiction where it would not otherwise be required to so qualify
or (ii) file any general consent to service of process in any such jurisdiction. The
Company will promptly advise the Representatives of the receipt by the Company of any
notification with respect to the suspension of the qualification of the Shares for offer or
sale in any such jurisdiction or the initiation or threatening of any proceeding for such
purpose.
(h) Reporting Requirements. During the period of five years hereafter, the Company will
furnish, upon request, to the Representatives and to each of the other Underwriters, as soon
as practicable after the end of each fiscal year, a copy of its annual report to
stockholders for such year; and the Company will furnish to the Representatives (i) as soon
as available, a copy of each report and any definitive proxy statement of the Company filed
with the Commission under the Exchange Act or mailed to stockholders, and (ii) from time to
time, such other information concerning the Company as the Representatives may reasonably
request. However, so long as the Company is subject to the reporting requirements of either
Section 13 or Section 15(d) of the Exchange Act and is timely filing reports with the
Commission on its Electronic Data Gathering, Analysis and Retrieval system (“XXXXX”), it is
not required to furnish such reports or statements to the Underwriters.
(i) Payment of Expenses. The Company will pay all expenses incident to the performance
of its obligations under this Agreement, including but not limited to any filing fees and
other expenses (including fees and disbursements of counsel to the Underwriters) incurred in
connection with qualification of the Shares for sale under the laws of such jurisdictions as
the Representatives designate and the preparation and printing of memoranda relating
thereto, costs and expenses related to any review by the Financial Industry Regulatory
Authority of the Shares (including filing fees and the fees and expenses of counsel for the
Underwriters relating directly to such review), costs and expenses relating to investor
presentations or any “road show” in connection with the offering and sale of the Shares
including, without limitation, any travel expenses of the Company’s officers and employees
and any other expenses of the Company including the chartering of airplanes and the cost of
lodging, meals, and other expenses for the Company, fees and expenses incident to listing
the Shares on NASDAQ, fees and expenses in connection with the registration of the Shares
under the Exchange Act, and expenses incurred in distributing preliminary prospectuses and
the Final Prospectus (including any amendments and supplements thereto) to the Underwriters
and for expenses incurred for preparing, printing and distributing any Issuer Free Writing
Prospectuses to investors or prospective investors. It is understood and acknowledged,
however, that, except as provided in this Agreement, the Underwriters will pay all of their
own costs and expenses, including fees of their counsel and transfer taxes on resale of any
of the Shares.
(j) Use of Proceeds. The Company will use the net proceeds from the sale of the Shares
in this offering in the manner set forth under the caption “Use of Proceeds” in the General
Disclosure Package and the Final Prospectus.
(k) Absence of Manipulation. The Company will not take, and will cause its
subsidiaries not to take, directly or indirectly, any action designed to cause or result in,
that constitutes or might reasonably be expected to cause or result in the stabilization or
manipulation of the price of any security of the Company to facilitate the sale or resale of
the Shares.
(l) Restriction on Sale of Common Stock. For the period specified below (the “Lock-Up
Period”), the Company will not, directly or indirectly, take any of the following actions
with respect to its
14
Common Stock or any securities convertible into or exchangeable or exercisable for any
of its Common Stock (“Lock-Up Securities”): (1) offer, sell, issue, contract to sell, pledge
or otherwise dispose of Lock-Up Securities, (2) offer, sell, issue, contract to sell, or
grant any option, right or warrant to purchase Lock-Up Securities, (3) enter into any swap,
hedge or any other agreement that transfers, in whole or in part, the economic consequences
of ownership of Lock-Up Securities, (4) establish or increase a put equivalent position or
liquidate or decrease a call equivalent position in Lock-Up Securities within the meaning of
Section 16 of the Exchange Act or (5) file with the Commission a registration statement
under the Act relating to Lock-Up Securities, or in each case publicly disclose the
intention to take any such action, without the prior written consent of Credit Suisse
Securities (USA) LLC, except for (i) the offer and sale of the Shares, (ii) the filing of a
registration statement on Form S-4 relating to the registration of shares of Common Stock
that may be issued in connection with an acquisition of another entity not in excess of a
specified percentage of the Company’s issued and outstanding shares of Common Stock as of
the date hereof set forth in a letter agreement dated as of the date hereof, between the
Company and the Representative and subject to any terms and conditions in such agreement,
(iii) the filing of a registration statement on Form S-8 relating to the registration of
shares of Common Stock that may be issued pursuant to equity plans described in the General
Disclosure Package, (iv) grants of employee stock options or other equity-based awards
pursuant to the terms of an equity compensation plan in effect on the date hereof and
described in the General Disclosure Package (including without limitation each such equity
compensation plan listed as an exhibit to the Company’s Annual Report on Form 10-K for the
year-ended December 31, 2009) or issuances of Lock-Up Securities pursuant to the exercise of
such options or other awards and (v) issuances pursuant to the exercise of the equity
appreciation instrument issued to the FDIC in connection with the Acquisition. The Lock-Up
Period will commence on the date hereof and continue for 90 days after the date hereof or
such earlier date that the Representatives consent to in writing.
6. Free Writing Prospectuses. The Company represents and agrees that, unless it obtains the
prior consent of the Representatives, and each Underwriter represents and agrees that, unless it
obtains the prior consent of the Company and the Representatives, it has not made and will not make
any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus, or that
would otherwise constitute a “free writing prospectus,” as defined in Rule 405, required to be
filed with the Commission. Any such free writing prospectus consented to by the Company and the
Representatives are hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company
represents that it has treated and agrees that it will treat each Permitted Free Writing Prospectus
as an “issuer free writing prospectus,” as defined in Rule 433, and has complied and will comply
with the requirements of Rules 164 and 433 applicable to any Permitted Free Writing Prospectus,
including timely Commission filing where required, legending and record keeping.
7. Conditions of the Obligations of the Underwriters. The obligations of the several
Underwriters to purchase and pay for the Firm Securities on the First Closing Date and the Optional
Securities to be purchased on each Optional Closing Date will be subject to the accuracy of the
representations and warranties of the Company herein (as though made on such Closing Date), to the
accuracy of the statements of Company officers made pursuant to the provisions hereof, to the
performance by the Company of its obligations hereunder and to the following additional conditions
precedent:
(a) Accountants’ Comfort Letter. The Representatives shall have received letters,
dated, respectively, the date hereof and each Closing Date, of Ernst & Young LLP confirming
that they are a registered public accounting firm and independent public accountants within
the meaning of the Securities Laws and substantially in the form of Schedule C
hereto (except that, in any letter dated a Closing Date, the specified date referred to in
Schedule C hereto shall be a date no more than three days prior to such Closing
Date).
(b) Filing of Prospectus. The Final Prospectus shall have been filed with the
Commission in accordance with the Rules and Regulations and Section 5(a) hereof. No stop
order suspending the effectiveness of the Registration Statement or of any part thereof
shall have been issued and no proceedings
15
for that purpose shall have been instituted or, to the knowledge of the Company or any
Underwriter, shall be contemplated by the Commission. The Registration Statement and all
amendments thereto shall not contain an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein
not misleading; the Prospectus, and any amendment or supplement thereto, shall not include
any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements therein, in the light of the circumstances under which they are
made, not misleading; and no Permitted Free Writing Prospectuses, if any, shall include an
untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they are made,
not misleading.
(c) No Material Adverse Change. Subsequent to the execution and delivery of this
Agreement, there shall not have occurred (i) any change, or any development or event
involving a prospective change, in the condition (financial or otherwise), results of
operations, business, properties or prospects of the Company and its subsidiaries taken as a
whole which, in the judgment of the Representatives, is material and adverse and makes it
impractical or inadvisable to market the Shares; (ii) any downgrading in the rating of any
debt securities (or, if applicable, preferred stock) of the Company by any “nationally
recognized statistical rating organization” (as defined for purposes of Rule 436(g)), or any
public announcement that any such organization has under surveillance or review its rating
of any debt securities (or, if applicable, preferred stock) of the Company (other than an
announcement with positive implications of a possible upgrading, and no implication of a
possible downgrading, of such rating) or any announcement that the Company has been placed
on negative outlook; (iii) any change in U.S. or international financial, political or
economic conditions or currency exchange rates or exchange controls the effect of which is
such as to make it, in the judgment of the Representatives, impractical or inadvisable to
market or to enforce contracts for the sale of the Shares, whether in the primary market or
in respect of dealings in the secondary market; (iv) any suspension or material limitation
of trading in securities generally on the NASDAQ or the New York Stock Exchange, or any
setting of minimum or maximum prices for trading on such exchanges; (v) or any suspension of
trading of any securities of the Company on any exchange or in the over-the-counter market;
(vi) any banking moratorium declared by any U.S. federal, New York or Ohio authorities;
(vii) any major disruption of settlements of securities, payment or clearance services in
the United States; or (viii) any attack on, outbreak or escalation of hostilities or act of
terrorism involving the United States, any declaration of war by Congress or any other
national or international calamity or emergency if, in the judgment of the Representatives,
the effect of any such attack, outbreak, escalation, act, declaration, calamity or emergency
is such as to make it impractical or inadvisable to market the Shares or to enforce
contracts for the sale of the Shares.
(d) Opinion of In-house Counsel for the Company. The Representatives shall have
received from the Company’s in-house counsel, Xxxxxx X. Xxxxxxx, Executive Vice President,
General Counsel and Secretary of the Company, an opinion substantially in the form of
Exhibit B hereto, dated as of such Closing Date.
(e) Opinion of Outside Counsel for the Company. The Representatives shall have
received from Vorys, Xxxxx, Xxxxxxx and Xxxxx LLP, the Company’s outside counsel, an opinion
substantially in the form of Exhibit C hereto, dated as of such Closing Date, and
the Company shall have furnished to such counsel such documents as they request for the
purpose of enabling them to pass upon such matters.
(f) Opinion of Counsel for the Underwriters. The Representatives shall have received
from Skadden, Arps, Slate, Xxxxxxx & Xxxx LLP, counsel for the Underwriters, an opinion and
a letter, dated as of such Closing Date, and the Company shall have furnished to such
counsel such documents as they request for the purpose of enabling them to pass upon such
matters.
16
(g) Officers’ Certificate. The Representatives shall have received a certificate of
the Chief Executive Officer and Chief Financial Officer of the Company, dated such Closing
Date, in which such officers shall state that: the representations and warranties of the
Company in this Agreement are true and correct; the Company has complied with all agreements
and satisfied all conditions on its part to be performed or satisfied hereunder at or prior
to such Closing Date; no stop order suspending the effectiveness of the Registration
Statement or of any part thereof has been issued and no proceedings for that purpose have
been instituted or, to the best of their knowledge and after reasonable investigation, are
contemplated by the Commission; and, subsequent to the respective dates of the most recent
financial statements included in or incorporated by reference into the General Disclosure
Package, there has been no material adverse change, nor any development or event involving a
prospective material adverse change, in the condition (financial or otherwise), results of
operations, business, properties or prospects of the Company and its subsidiaries taken as a
whole except as set forth in the General Disclosure Package or as described in such
certificate.
(h) Chief Financial Officer’s Certificate. The Representatives shall have received a
certificate, dated the date hereof, and a bring-down certificate, dated each Closing Date,
of the principal financial or accounting officer of the Company substantially in the form of
Schedule D hereto.
(i) Lock-Up Agreements. The “lock-up” agreements, each substantially in the form of
Exhibit A hereto, between the Representatives, officers and directors of the Company
set forth on Schedule E hereto relating to sales and certain other dispositions of
Common Stock or certain other securities, shall have been delivered to the Representatives
on or before the date hereof, and are in full force and effect at each Closing Date.
(j) Listing. The Shares shall have been approved for listing on the NASDAQ Global
Select Market, subject only to notice of issuance at or prior to each Settlement Date.
The Company will furnish the Representatives with such conformed copies of such opinions,
certificates, letters and documents as the Representatives reasonably request. The
Representatives may in their sole discretion waive on behalf of the Underwriters compliance
with any conditions to the obligations of the Underwriters hereunder, whether in respect of
an Optional Closing Date or otherwise.
8. Indemnification and Contribution.
(a) Indemnification of the Underwriters. The Company will indemnify and hold harmless
each Underwriter, its partners, members, directors, officers, employees, agents, affiliates
and each person, if any, who controls such Underwriter within the meaning of Section 15 of
the Act or Section 20 of the Exchange Act (each, an “Indemnified Party”), against any and
all losses, claims, damages or liabilities, joint or several, to which such Indemnified
Party may become subject, under the Act, the Exchange Act, other federal or state statutory
law or regulation or otherwise, insofar as such losses, claims, damages or liabilities (or
actions in respect thereof) arise out of or are based upon (i) any untrue statement or
alleged untrue statement of any material fact contained in any part of the Registration
Statement, or the omission or alleged omission therefrom of a material fact required to be
stated therein or necessary to make the statements therein not misleading or (ii) any untrue
statement or alleged untrue statement of any material fact contained in any Statutory
Prospectus, Final Prospectus or any Issuer Free Writing Prospectus, or any “road show” (as
defined in Rule 433 under the Act) not constituting an Issuer Free Writing Prospectus (a
“Non-Prospectus Road Show”) or any amendment or supplement thereto, or arise out of or are
based upon the omission or alleged omission therefrom of a material fact necessary in order
to make the statements therein, in light of the circumstances under which they were made,
not misleading, and will reimburse each
17
Indemnified Party for any legal or other expenses reasonably incurred by such
Indemnified Party in connection with investigating or defending against any loss, claim,
damage, liability, action, litigation, investigation or proceeding whatsoever (whether or
not such Indemnified Party is a party thereto), whether threatened or commenced, and in
connection with the enforcement of this provision with respect to any of the above as such
expenses are incurred; provided, however, that the Company will not be liable in any such
case to the extent that any such loss, claim, damage or liability arises out of or is based
upon an untrue statement or alleged untrue statement in or omission or alleged omission from
any of such documents in reliance upon and in conformity with written information furnished
to the Company by any Underwriter through the Representatives specifically for use therein,
it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in subsection (b) below.
(b) Indemnification of the Company. Each Underwriter will severally and not jointly
indemnify and hold harmless the Company, each of its directors and each of its officers who
signs a Registration Statement and each person, if any, who controls the Company within the
meaning of Section 15 of the Act or Section 20 of the Exchange Act (each, an “Underwriter
Indemnified Party”), against any losses, claims, damages or liabilities to which such
Underwriter Indemnified Party may become subject, under the Act, the Exchange Act, other
federal or state statutory law or regulation or otherwise, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based upon (i)
any untrue statement or alleged untrue statement of any material fact contained in any part
of the Registration Statement, or the omission or alleged omission therefrom of a material
fact required to be stated therein or necessary to make the statements therein not
misleading or (ii) any untrue statement or alleged untrue statement of any material fact
contained in any Statutory Prospectus, Final Prospectus or any Issuer Free Writing
Prospectus, or any Non-Prospectus Road Show or any amendment or supplement thereto or arise
out of or are based upon the omission or alleged omission therefrom of a material fact
necessary in order to make the statements therein, in light of the circumstances under which
they were made, not misleading, in each case to the extent, but only to the extent, that
such untrue statement or alleged untrue statement or omission or alleged omission was made
in reliance upon and in conformity with written information furnished to the Company by such
Underwriter through the Representatives specifically for use therein, and will reimburse any
legal or other expenses reasonably incurred by such Underwriter Indemnified Party in
connection with investigating or defending against any such loss, claim, damage, liability,
action, litigation, investigation or proceeding whatsoever (whether or not such Underwriter
Indemnified Party is a party thereto), whether threatened or commenced, based upon any such
untrue statement or omission, or any such alleged untrue statement or omission as such
expenses are incurred, it being understood and agreed that the only such information
furnished by any Underwriter through the Representatives consists of the following
information in the Preliminary Prospectus Supplement and the Final Prospectus: the
concession figure appearing in the fourth paragraph under the caption “Underwriting” and the
twelfth paragraph under the caption “Underwriting” to the extent concerning stabilizing
transactions. The Company and the Representatives acknowledge that no information has been
furnished to the Company by any Underwriter through the Representatives for use in any
Non-Prospectus Road Show.
(c) Actions Against Parties; Notification. Promptly after receipt by an indemnified
party under this Section of notice of the commencement of any action, such indemnified party
will, if a claim in respect thereof is to be made against the indemnifying party under
subsection (a) or (b) above, notify the indemnifying party of the commencement thereof;
provided that the failure to notify the indemnifying party shall not relieve it from any
liability that it may have under subsection (a) or (b) above except to the extent that it
has been materially prejudiced (through the forfeiture of substantive rights or defenses) by
such failure; and provided further that the failure to notify the indemnifying party shall
not relieve it from any liability that it may have to an indemnified party otherwise than
under subsection (a) or (b) above. In case any such action is brought against any
indemnified party and it notifies the indemnifying party of the commencement thereof, the
indemnifying party will be entitled to participate therein and, to the extent that it may
wish, jointly with any other indemnifying party similarly notified, to assume the defense
thereof, with counsel satisfactory to such indemnified party (who shall not, except with the
consent of the
18
indemnified party, be counsel to the indemnifying party), and after notice from the
indemnifying party to such indemnified party of its election so to assume the defense
thereof, the indemnifying party will not be liable to such indemnified party under this
Section for any legal or other expenses subsequently incurred by such indemnified party in
connection with the defense thereof other than reasonable costs of investigation; provided,
however, if such indemnified party shall have been advised by counsel that there are one or
more defenses available to it that are in conflict with those available to the indemnifying
party (in which case the indemnifying party shall not have the right to direct the defense
of such action on behalf of the indemnified party), the reasonable fees and expenses of such
indemnified party’s counsel shall be borne by the indemnifying party. In no event shall the
indemnifying party be liable for the fees and expenses of more than one counsel (together
with appropriate local counsel) at any time for any indemnified party in connection with any
one action or separate but substantially similar or related actions arising in the same
jurisdiction out of the same general allegations or circumstances. No indemnifying party
shall, without the prior written consent of the indemnified party, effect any settlement of
any pending or threatened action in respect of which any indemnified party is or could have
been a party and indemnity could have been sought hereunder by such indemnified party unless
such settlement (i) includes an unconditional release of such indemnified party from all
liability on any claims that are the subject matter of such action and (ii) does not include
a statement as to, or an admission of, fault, culpability or a failure to act by or on
behalf of an indemnified party.
(d) Contribution. If the indemnification provided for in this Section is unavailable
or insufficient to hold harmless an indemnified party under subsection (a) or (b) above,
then each indemnifying party shall contribute to the amount paid or payable by such
indemnified party as a result of the losses, claims, damages or liabilities referred to in
subsection (a) or (b) above (i) in such proportion as is appropriate to reflect the relative
benefits received by the Company on the one hand and the Underwriters on the other from the
offering of the Shares or (ii) if the allocation provided by clause (i) above is not
permitted by applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to in clause (i) above but also the relative fault of the Company
on the one hand and the Underwriters on the other in connection with the statements or
omissions which resulted in such losses, claims, damages or liabilities as well as any other
relevant equitable considerations. The relative benefits received by the Company on the one
hand and the Underwriters on the other shall be deemed to be in the same proportion as the
total net proceeds from the offering (before deducting expenses) received by the Company
bear to the total underwriting discounts and commissions received by the Underwriters from
the offering under this Agreement. The relative fault shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information supplied by the
Company or the Underwriters and the parties’ relative intent, knowledge, access to
information and opportunity to correct or prevent such untrue statement or omission. The
amount paid by an indemnified party as a result of the losses, claims, damages or
liabilities referred to in the first sentence of this subsection (d) shall be deemed to
include any legal or other expenses reasonably incurred by such indemnified party in
connection with investigating or defending any action or claim which is the subject of this
subsection (d). Notwithstanding the provisions of this subsection (d), no Underwriter shall
be required to contribute any amount in excess of the amount by which the total price at
which the shares of Common Stock underwritten by it and distributed to the public were
offered to the public exceeds the amount of any damages which such Underwriter has otherwise
been required to pay by reason of such untrue or alleged untrue statement or omission or
alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The Underwriters’ obligations in this
subsection (d) to contribute are several in proportion to their respective underwriting
obligations and not joint. The Company and the Underwriters agree that it would not be just
and equitable if contribution pursuant to this Section 8(d) were determined by pro rata
allocation (even if the Underwriters were treated as one entity for such purpose) or by any
other method of allocation which does not take account of the equitable considerations
referred to in this Section 8(d).
9. Default of Underwriters. If any Underwriter or Underwriters default in their obligations
to purchase Shares hereunder on either the First or any Optional Closing Date and the aggregate
number of Shares that
19
such defaulting Underwriter or Underwriters agreed but failed to purchase does not exceed 10%
of the total number of Shares that the Underwriters are obligated to purchase on such Closing Date,
the Representatives may make arrangements satisfactory to the Company for the purchase of such
Shares by other persons, including any of the Underwriters, but if no such arrangements are made by
such Closing Date, the non-defaulting Underwriters shall be obligated severally, in proportion to
their respective commitments hereunder, to purchase the Shares that such defaulting Underwriters
agreed but failed to purchase on such Closing Date. If any Underwriter or Underwriters so default
and the aggregate number of Shares with respect to which such default or defaults occur exceeds 10%
of the total number of Shares that the Underwriters are obligated to purchase on such Closing Date
and arrangements satisfactory to the Representatives and the Company for the purchase of such
Shares by other persons are not made within 36 hours after such default, this Agreement will
terminate without liability on the part of any non-defaulting Underwriter or the Company, except as
provided in Section 10 (provided that if such default occurs with respect to Optional Securities
after the First Closing Date, this Agreement will not terminate as to the Firm Securities or any
Optional Securities purchased prior to such termination). As used in this Agreement, the term
“Underwriter” includes any person substituted for an Underwriter under this Section. Nothing herein
will relieve a defaulting Underwriter from liability for its default.
10. Survival of Certain Representations and Obligations. The respective indemnities,
agreements, representations, warranties and other statements of the Company or its officers and of
the several Underwriters set forth in or made pursuant to this Agreement will remain in full force
and effect, regardless of any investigation, or statement as to the results thereof, made by or on
behalf of any Underwriter, the Company or any of their respective representatives, officers or
directors or any controlling person, and will survive delivery of, and payment for, the Shares. If
the purchase of the Shares by the Underwriters is not consummated for any reason other than solely
because of the termination of this Agreement pursuant to Section 9 hereof, the Company will
reimburse the Underwriters for all out-of-pocket expenses (including fees and disbursements of
counsel) reasonably incurred by them in connection with the offering of the Shares, and the
respective obligations of the Company and the Underwriters pursuant to Section 8 hereof shall
remain in effect. In addition, if any Shares have been purchased hereunder, the representations
and warranties in Section 2 and all obligations under Section 5 shall also remain in effect.
11. Research Independence. The Company acknowledges that any Underwriter’s research analysts
and research departments are required to be independent from their respective investment banking
divisions and are subject to certain regulations and internal policies, and that such
Underwriters’s research analysts may hold and make statements or investment recommendations and/or
publish research reports with respect to the Company and/or the offering that differ from the views
of their investment bankers. The Company hereby waives and releases, to the fullest extent
permitted by law, any claims that the Company may have against each Underwriter with respect to any
conflict of interest that may arise from the fact that the views expressed by such Underwriter’s
independent research analysts and research departments may be different from or inconsistent with
the views or advice communicated to the Company by such Underwriter’s investment banking divisions.
The Company acknowledges that each Underwriter is a full service securities firm and as such from
time to time, subject to applicable securities laws, may effect transactions for its own accounts
or the accounts of its customers and hold long or short positions in debt or equity securities of
the companies that may be the subject of the transactions contemplated by the Underwriting
Agreement.
12. Notices. All communications hereunder will be in writing and, if sent to the Underwriters,
will be mailed, delivered or faxed and confirmed to the Representatives c/o Credit Suisse
Securities (USA) LLC, Eleven Xxxxxxx Xxxxxx, Xxx Xxxx, XX 00000-0000, Attention: LCD-IBD, c/o RBC
Capital Markets Corporation, Three World Financial Center, 000 Xxxxx Xxxxxx, 0xx Xxxxx, Xxx Xxxx,
Xxx Xxxx 00000-0000, Attention: Xxx Xxxxx, Equity Capital Markets, and Sandler X’Xxxxx & Partners,
L.P., 000 Xxxxx Xxxxxx, Xxx Xxxx, XX 00000, Attention Xxx Xxxxxxxx, Equity Syndicate, or, if sent
to the Company, will be mailed, delivered or faxed and confirmed to it at FirstMerit Corporation,
III Xxxxxxx Xxxxx, 0xx Xxxxx, Xxxxx, XX 00000 Attention: Xxxxxx X. Xxxxxxx, Executive
Vice President, General Counsel and Secretary; provided, however, that any notice to an Underwriter
pursuant to Section 8 will be mailed, delivered or faxed and confirmed to such Underwriter.
20
13. Successors. This Agreement will inure to the benefit of and be binding upon the parties
hereto and their respective successors and the officers and directors and controlling persons
referred to in Section 8, and no other person will have any right or obligation hereunder.
14. Representation of the Underwriters. The Representatives will act for the several
Underwriters in connection with this financing, and any action under this Agreement taken by the
Representatives (or Credit Suisse Securities (USA) LLC individually on behalf of the
Representatives) will be binding upon all the Underwriters.
15. Counterparts. This Agreement may be executed by facsimile or other electronic signatures
in any number of counterparts, each of which shall be deemed to be an original, but all such
counterparts shall together constitute one and the same Agreement.
16. Absence of Fiduciary Relationship. The Company acknowledges and agrees that:
(a) No Other Relationship. The Underwriters have been retained solely to act as
underwriters in connection with the sale of the Shares and that no fiduciary, advisory or
agency relationship between the Company and the Underwriters has been created in respect of
any of the transactions contemplated by this Agreement or the Final Prospectus, irrespective
of whether the Underwriters have advised or is advising the Company on other matters;
(b) Arms’ Length Negotiations. The price of the Shares set forth in this Agreement was
established by the Company following discussions and arms-length negotiations with the
Underwriters and the Company is capable of evaluating and understanding and understands and
accepts the terms, risks and conditions of the transactions contemplated by this Agreement;
(c) Absence of Obligation to Disclose. The Company has been advised that the
Underwriters have and its affiliates are engaged in a broad range of transactions which may
involve interests that differ from those of the Company and that the Underwriters have no
obligation to disclose such interests and transactions to the Company by virtue of any
fiduciary, advisory or agency relationship; and
(d) Waiver. The Company waives, to the fullest extent permitted by law, any claims it
may have against the Underwriters for breach of fiduciary duty or alleged breach of
fiduciary duty and agrees that the Underwriters shall have no liability (whether direct or
indirect) to the Company in respect of such a fiduciary duty claim or to any person
asserting a fiduciary duty claim on behalf of or in right of the Company, including
stockholders, employees or creditors of the Company.
17. Applicable Law. This Agreement shall be governed by, and construed in accordance with,
the laws of the State of New York.
The Company hereby submits to the non-exclusive jurisdiction of the federal and state courts
in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or
relating to this Agreement or the transactions contemplated hereby. The Company irrevocably and
unconditionally waives any objection to the laying of venue of any suit or proceeding arising out
of or relating to this Agreement or the transactions contemplated hereby in federal and state
courts in the Borough of Manhattan in The City of New York and irrevocably and unconditionally
waives and agrees not to plead or claim in any such court that any such suit or proceeding in any
such court has been brought in an inconvenient forum.
21
Each of the Underwriters and the Company (on its behalf and, to the extent permitted by
applicable law, on behalf of its shareholders and affiliates) waives all right to trial by jury in
any action, proceeding or counterclaim (whether based upon contract, tort or otherwise) in any way
arising out of or relating to this Agreement.
[Remainder of Page Intentionally Left Blank]
22
If the foregoing is in accordance with the Representatives’ understanding of our agreement,
kindly sign and return to the Company one of the counterparts hereof, whereupon it will become a
binding agreement between the Company and the several Underwriters in accordance with its terms.
Very truly yours, FirstMerit Corporation |
||||
By: | /s/ Xxxx X. Xxxxx | |||
Name: | Xxxx X. Xxxxx | |||
Title: | Chairman, President and CEO | |||
The foregoing Underwriting Agreement is hereby
confirmed and accepted as of the date first
above written.
Credit Suisse Securities (USA) LLC |
||||
By: | /s/ Xxxxxxx X. Xxxxxxx | |||
Name: | Xxxxxxx X. Xxxxxxx | |||
Title: | Director | |||
RBC Capital Markets Corporation |
||||
By: | /s/ Xxxxxx Xxxxx | |||
Name: | Xxxxxx Xxxxx | |||
Title: | Managing Director | |||
Sandler X’Xxxxx & Partners, L.P. By: Sandler X’Xxxxx & Partners Corp., the sole general partner |
||||
By: | /s/ Xxxxxx X. Xxxxxxxx | |||
Name: | Xxxxxx X. Xxxxxxxx | |||
Title: | Principal, Head of Syndicate | |||
Acting on behalf of itself and as the Representatives
of the several Underwriters
23
SCHEDULE A
Number of | ||||
Underwriter | Firm Securities | |||
Credit Suisse Securities (USA) LLC |
5,526,316 | |||
RBC Capital Markets Corporation |
5,526,316 | |||
Sandler X’Xxxxx & Partners, L.P. |
5,526,315 | |||
Total |
16,548,947 | |||
SCHEDULE B
1. | General Use Free Writing Prospectuses (included in the General Disclosure Package) | |
“General Use Issuer Free Writing Prospectus” includes each of the following documents: |
1. | Issuer Free Writing Prospectus filed with the Commission on May 17, 2010. |
2. | Other Information Included in the General Disclosure Package | |
The following information is also included in the General Disclosure Package: |
1. | The initial price to the public of the Shares: $19.00. | ||
2. | Number of Firm Securities: 16,578,947 | ||
3. | Number of Optional Securities: 2,486,842 |
SCHEDULE C
The Representatives shall have received letters, dated, respectively, the date hereof and the
each Closing Date confirming that they are a registered public accounting firm and independent
public accountants within the meaning of the Securities Laws to the effect that:
SCHEDULE D
CFO Certificate
SCHEDULE E
Officers and Directors of the Company Signing Lock-Up Agreements
Xxxx X. Xxxxx, Chairman of the Board, President & Chief Executive Officer
Xxxxxxxx X. Xxxxxxx, Executive Vice President & Chief Financial Officer
Xxxxxxx X. Xxxxxxx, Executive Vice President, Wealth Management Services
Xxxxx X. Xxxxxxx, Executive Vice President, Commercial Banking
Xxxxxxxxxxx X. Xxxxxx, Executive Vice President, Human Resources
Xxxxxxx X. Xxxxxxxx, Executive Vice President & Chief Credit Officer
Xxxxx X. Xxxxx, Executive Vice President & Chief Technology Officer
Xxxxxx X. Xxxxxxx, Executive Vice President, Risk Management, General Counsel and Secretary
Xxxxxxxx X. Xxxxxx, Lead Director
Xxxxxx X. Xxxx, Director
Xxxxx X. Xxxxxx, Director
R. Xxxx Xxxxx, Director
Xxxx X. Xxxxxxx, Director
Xxxxxx X. Xxxxxx, Director
Xxxxxxx X. Xxxxxxx, Director
Xxxx X. France, Director
Xxxxx X. Xxxxxx, Director
J. Xxxxxxx Xxxxxxxxxxxxx, Director
Xxxxxx X. Xxxxx XX, Director
EXHIBIT A
Lock-Up Letter Agreement
May 17, 2010
FirstMerit Corporation
III Xxxxxxx Xxxxx, 0xx Xxxxx
Xxxxx, XX 00000
III Xxxxxxx Xxxxx, 0xx Xxxxx
Xxxxx, XX 00000
RBC Capital Markets Corporation
Xxx Xxxxxxx Xxxxx
Xxx Xxxx, XX 00000
Xxx Xxxxxxx Xxxxx
Xxx Xxxx, XX 00000
Sandler X’Xxxxx & Partners, L.P.
000 Xxxxx Xxxxxx
Xxx Xxxx, XX 00000
000 Xxxxx Xxxxxx
Xxx Xxxx, XX 00000
As Representatives of the several Underwriters named in the Underwriting Agreement
Dear Sirs:
As an inducement to the Underwriters to execute the Underwriting Agreement, pursuant to which
an offering will be made that is intended to result in an orderly market for the common stock (the
“Securities”) of FirstMerit Corporation, and any successor (by merger or otherwise) thereto (the
“Company”), the undersigned hereby agrees that during the period specified in the following
paragraph (the “Lock-Up Period”), the undersigned will not offer, sell, contract to sell, pledge or
otherwise dispose of, directly or indirectly, any Securities or securities convertible into or
exchangeable or exercisable for any Securities, enter into a transaction which would have the same
effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in part, any
of the economic consequences of ownership of the Securities, whether any such aforementioned
transaction is to be settled by delivery of the Securities or such other securities, in cash or
otherwise, or publicly disclose the intention to make any such offer, sale, pledge or disposition,
or to enter into any such transaction, swap, hedge or other arrangement, without, in each case, the
prior written consent of Credit Suisse Securities (USA) LLC (“Credit Suisse”); provided,
however, that the undersigned may effect an exchange or sale of Securities solely in
connection with a “cashless” exercise of stock options granted by the Company to the undersigned.
In addition, the undersigned agrees that, without the prior written consent of Credit Suisse, it
will not, during the Lock-Up Period, make any demand for or exercise any right with respect to, the
registration of any Securities or any security convertible into or exercisable or exchangeable for
the Securities.
The Lock-Up Period will commence on the date of this Lock-Up Agreement and continue and
include the date 90 days after the public offering date set forth on the final prospectus
supplement used to sell the Securities (the “Public Offering Date”) pursuant to the Underwriting
Agreement governing the terms of the offering.
Any Securities received upon exercise of options granted to the undersigned will also be
subject to this Lock-Up Agreement. Any Securities acquired by the undersigned in the open market
will not be subject to this Lock-Up Agreement. A transfer of Securities to a family member or
trust may be made, provided the transferee agrees to be bound in writing by the terms of this
Lock-Up Agreement prior to such transfer, such transfer shall not involve a disposition for value
and no filing by any party (donor, donee, transferor or transferee) under the Securities Exchange
Act of 1934 (the “Exchange Act”) shall be required or shall be voluntarily made in connection with
such transfer (other than a filing on a Form 5 made after the expiration of the Lock-Up Period).
30
In furtherance of the foregoing, the Company and its transfer agent and registrar are hereby
authorized to decline to make any transfer of shares of Securities if such transfer would
constitute a violation or breach of this Lock-Up Agreement.
This Lock-Up Agreement shall be binding on the undersigned and the successors, heirs, personal
representatives and assigns of the undersigned. This Lock-Up Agreement shall lapse and become null
and void at the earliest of (i) the time the Company notifies you in writing that it does not
intend to proceed with the offering contemplated by the Underwriting Agreement, (ii) the
Underwriting Agreement is terminated for any reason prior to the sale of the Securities to the
Underwriters and (iii) the Public Offering Date shall not have occurred on or before May 28, 2010.
This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the
State of New York.
Very truly yours,
31
EXHIBIT B
In-House Counsel Opinion
EXHIBIT C
Vorys, Xxxxx, Xxxxxxx and Xxxxx LLP Opinion